<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248299</url>
  </required_header>
  <id_info>
    <org_study_id>E-DIS 2010-06</org_study_id>
    <secondary_id>2010-021439-16</secondary_id>
    <nct_id>NCT01248299</nct_id>
  </id_info>
  <brief_title>Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.</brief_title>
  <acronym>E-DIS</acronym>
  <official_title>A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable Toxicity After a 6-weeks Chemotherapy Course .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interest of continuing systemic chemotherapy or not , after a short initial treatment (6
      weeks) in patients who are in response or stable disease(&quot;Discontinuation design &quot;)of
      patients with metastatic oesophageal cancer of squamous cell type

      The secondary aims would be to study : toxicity, the overall survival rate, a study of costs
      and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As the data in litterature does not provide the basis for well-argued statistical hypothesis,
      it is suggested to randomize 30 patients per arm. An IDMC will come to a decision after the
      inclusion of 10, 20 ans 40 patients on the efficacy and the toxicity profile and on whether
      to maintain the current clinical position, justifying randomisation . In order to take into
      account any possible effects of prior concomitant radiochemotherapy, patient will be
      stratified according to whether they have already undergone chemotherapy or
      radiochemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Between the date of randomisation and the date of death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Between the date of randomisation and the date of progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>At each visit : every 6 weeks</time_frame>
    <description>According to the NCI-CTCAE V4.0 grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Every 6 weeks</time_frame>
    <description>EOTRC QLQ-C30 questionnaire and the oesophagus QLQ-OES18 module
EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
    <time_frame>Every 6 weeks</time_frame>
    <description>Data collected :
Hospitalization
day hospital visit
Chemotherapy drugs administered
Home medical care
Radiotherapy
Oncologist visits, General Practitioner Visits
Laboratory and radiologic tests</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Squamous Cell Carcinoma of Esophagus</condition>
  <arm_group>
    <arm_group_label>Chemotherapy plus best supportive care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy plus best supportive care with follow up at each cycle of the treatment with FU-CDDP; LV5FU2-CDDP; FOLFOX; TPF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best supportive care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best supportive care with follow up every 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FU-CDDP</intervention_name>
    <description>every 21 days:
Fluoro-uracil [800 mg/m2, day 1 to day 5]
CisPlatin [75 mg/m2, day 1 or day 2]</description>
    <arm_group_label>Chemotherapy plus best supportive care</arm_group_label>
    <other_name>Fluoro-uracil+CisPlatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU2-CDDP</intervention_name>
    <description>every 14 days:
Elvorin [200 mg/m2, 2h IV, day 1 and day 2]
Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]
Fluoro-uracil [600 mg/m2, 22h continous infusion, day 1 and day 2]
CisPlatin [50 mg/m2, day 2]</description>
    <arm_group_label>Chemotherapy plus best supportive care</arm_group_label>
    <other_name>Elvorin+Fluoro-uracil+CisPlatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>every 14 days:
Oxaliplatin [85 mg/m2 by 2h infusion, day 1]
Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]
Fluoro-uracil [600 mg/m2, by 22h continous infusion, day 1 and day 2]
Elvorin [500 mg/m2, day 1 and day 2]</description>
    <arm_group_label>Chemotherapy plus best supportive care</arm_group_label>
    <other_name>Oxaliplatin+Fluoro-uracil+Elvorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF</intervention_name>
    <description>every 21 days:
Docetaxel [30 mg/m2, day 1 and day 8]
CisPlatin [60 mg/m2, day 1]
Fluoro-uracil [200 mg/m2/day by continous infusion]
Or every 21 days:
Docetaxel [50 mg/m2, day 1]
CisPlatine [70 mg/m2, day 1]
Fluoro-uracile [700 mg/m2 /day, day 1 to day 5]</description>
    <arm_group_label>Chemotherapy plus best supportive care</arm_group_label>
    <other_name>Docetaxel+CisPlatine+Fluoro-uracile</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...</description>
    <arm_group_label>Best supportive care</arm_group_label>
    <other_name>antalgic treatment, nutritional support, ...</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an histologically proven epidermoid cancer of the oesophagus

          -  Patients with metastatic disease that can be measured or evaluated according to the
             RECIST criteria, and located outside of previously irradiated fields

          -  Patients who may or may not have undergone radiochemotherapy

          -  Patients who have not received chemotherapy for metastatic disease

          -  ≥ 18 ans

          -  Performance Status (ECOG) ≤ 2

          -  People who are covered by private or state health insurance

          -  Informed consent signed by the patient

        Exclusion Criteria:

          -  Other evolutive malignant tumor

          -  Infection with HIV-1, HIV-2 or chronic hepatitis B or C

          -  Cerebral metastasis or known meningeal tumor

          -  Any unstable chronic diseases that could risk the safety or the compliance of te
             patient

          -  Women who are pregnant or breastfeeding. Women must not breastfeed for at least 6
             months after administration of Bevacizumab

          -  Patients unable to undergo the follow-up of the trial for geographical, social or
             psychological reasons

        For the randomized part

        Inclusion criteria :

          -  Non-progressive disease after the 6 first weeks of chemotherapy

          -  Performance Status (ECOG) ≤ 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine ADENIS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Nantes Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la Theuillerie</name>
      <address>
        <city>Ris Orangis</city>
        <zip>91130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Armoricaine</name>
      <address>
        <city>St-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Villeneuve St Georges</city>
        <zip>94190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Best Supportive Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

